Sio Capital Management’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-243,035
Closed -$5.18M 64
2024
Q1
$5.18M Sell
243,035
-3,001
-1% -$35.9K 1.54% 22
2023
Q4
$2.36M Hold
246,036
0.54% 23
2023
Q3
$640K Hold
246,036
0.2% 42
2023
Q2
$1.15M Hold
246,036
0.29% 33
2023
Q1
$928K Sell
246,036
-14,412
-6% -$56.7K 0.46% 32
2022
Q4
$820K Hold
260,448
0.3% 36
2022
Q3
$784K Hold
260,448
0.25% 36
2022
Q2
$649K Buy
260,448
+685
+0.3% +$3.15K 0.24% 46
2022
Q1
$2.02M Hold
259,763
0.67% 35
2021
Q4
$1.08M Hold
259,763
0.33% 54
2021
Q3
$2.06M Sell
259,763
-6,344
-2% -$53.4K 0.66% 42
2021
Q2
$2.15M Buy
266,107
+16,688
+7% +$144K 0.53% 53
2021
Q1
$2.67M Buy
249,419
+76,726
+44% +$897K 0.54% 57
2020
Q4
$2.03M Buy
+172,693
New +$2.17M 0.42% 68
2020
Q3
Sell
-3,000
Closed -$52K 103
2020
Q2
$52K Buy
+3,000
New +$52.3K 0.02% 78

Sio Capital Management's FUSN Position: Q2 2024 in Review

Sio Capital Management sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 243,035 shares — an estimated $5.18M sold.

Sio Capital Management first reported a position in FUSN in Q2 2020 and held it in 15 quarters. The position peaked at $5.18M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

  • Sio Capital Management reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
  • Sio Capital Management sold 243,035 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $5.18M.
  • Sio Capital Management first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 15 quarters.
  • Sio Capital Management's Fusion Pharmaceuticals Inc. Common Shares position peaked at $5.18M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Sio Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.